Viewing
News|Articles|November 19, 2026

First patient dosed in EMERALD trial of EO2002 for corneal edema

Author(s)Anita Shiva

The phase 2 EMERALD trial compares 2 doses of EO2002 with placebo, with a 15-letter BCVA gain at 26 weeks as the primary end point.

Emmecell has dosed the first participant in EMERALD (NCT07729137), a phase 2 trial of the investigational cell therapy EO2002 (Emmecell) for corneal edema secondary to corneal endothelial dysfunction. The randomized, double-masked, placebo-controlled study will test whether a single intracameral injection of donor-derived corneal endothelial cells improves best-corrected visual acuity (BCVA) at 26 weeks.1

Advanced endothelial disease is currently managed with keratoplasty, most often endothelial keratoplasty, a procedure requiring donor corneal tissue and a corneal surgeon.1 Emmecell is developing EO2002 as a less invasive option, and the FDA granted the therapy Regenerative Medicine Advanced Therapy (RMAT) designation in July 2026.2

“Corneal endothelial dysfunction can significantly affect patients’ vision and daily activities, and additional treatment options are needed. EMERALD will help us understand whether an injection of magnetic corneal endothelial cells can improve vision and corneal clarity. We are pleased to contribute to this evaluation,” Jennifer Nottage, MD, an investigator in the EMERALD study, said in the news release.1

How is the phase 2 EMERALD trial of EO2002 designed?

EMERALD is a multicenter US study enrolling adults with corneal edema caused by endothelial dysfunction, including patients with Fuchs endothelial corneal dystrophy (FECD) and patients with pseudophakic bullous keratopathy. Participants must be considered surgical candidates for full-thickness corneal transplantation or endothelial keratoplasty. Participants are randomly assigned to 1 of 3 arms: a single intracameral injection of EO2002 at 150,000 cells, a single injection at 500,000 cells, or placebo. Both participants and investigators are masked to treatment assignment.1,3

The primary end point is the proportion of study eyes gaining 15 or more letters in BCVA at week 26 compared with baseline. The study also examines mean change in visual acuity, change in central corneal thickness and safety, with follow-up continuing through week 52.1,3

The company describes EMERALD as the first of 2 trials in a planned registrational program. Emmecell noted its registrational strategy depends on clinical results and on discussions with the FDA. Testing 2 active doses allows the study to compare outcomes across cell counts, while the placebo arm serves as a masked control for changes in visual acuity and corneal thickness.1

What is EO2002 and how does magnetic cell delivery work?

EO2002 is an investigational allogeneic therapy consisting of cultured human corneal endothelial cells derived from donor tissue. The cells are magnetically labeled before injection into the anterior chamber, and a magnetic patch placed on the outside of the eye is intended to steer them toward the posterior cornea so more of them attach to the endothelial surface. Emmecell refers to this approach as its Magnetic Cell Delivery platform.1

By repopulating the endothelium through an injection, the company aims to avoid grafting donor tissue and the specialized surgery keratoplasty requires. RMAT designation gives Emmecell more frequent opportunities to interact with the FDA on trial design, manufacturing, and review as development continues. EO2002 is not approved for commercial use. Beyond the cornea, Emmecell is also studying its delivery platform in retinal disease.1,4

“Starting dosing in EMERALD is an important step toward evaluating a different treatment approach for patients with corneal endothelial disease. Our goal is to restore corneal function through a single injection and reduce the burden of transplant surgery. This randomized, placebo-controlled study is designed to generate the evidence needed to evaluate that potential and guide the next stage of EO2002’s development. We thank the patients, investigators and study teams making this work possible,” Ramin Valian, chief executive officer of Emmecell, stated in the news release.1

Frequently Asked Questions

What is EO2002?
EO2002 is an investigational allogeneic corneal endothelial cell therapy from Emmecell, given as a single intracameral injection for corneal edema secondary to corneal endothelial dysfunction.1 It is not FDA approved, but was granted RMAT designation in July 2026.2

How does EO2002 work?
Cultured donor endothelial cells are magnetically labeled and injected into the anterior chamber, where an external magnetic patch is designed to guide them to the posterior cornea to improve cell retention.1

What should optometrists know about the EMERALD trial?
EMERALD is a phase 2, placebo-controlled trial comparing 2 doses of EO2002, with a gain of 15 or more BCVA letters at week 26 as the primary endpoint.1

This content was generated with the assistance of artificial intelligence.

References
1. Emmecell announces first patient dosed in EMERALD study of magnetic cell therapy for corneal endothelial disease. News release. Emmecell. November 18, 2026. Accessed November 18, 2026. https://www.businesswire.com/news/home/20261118271215/en/Emmecell-Announces-First-Patient-Dosed-in-EMERALD-Study-of-Magnetic-Cell-Therapy-for-Corneal-Endothelial-Disease
2. Ophthalmology Times Staff Reports. FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease. Ophthalmology Times. July 7, 2026. Accessed November 18, 2026. https://www.ophthalmologytimes.com/view/fda-grants-rmat-designation-to-emmecell-s-eo2002-for-corneal-endothelial-disease
3. Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (EMERALD). ClinicalTrials.gov. Updated October 9, 2026. Accessed November 18, 2026. https://www.clinicaltrials.gov/study/NCT07729137
4. Emmecell receives FDA Regenerative Medicine Advanced Therapy (RMAT) designation for EO2002 for the treatment of corneal endothelial disease. News release. Emmecell. July 7, 2026. Accessed November 18, 2026. https://www.biospace.com/press-releases/emmecell-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-eo2002-for-the-treatment-of-corneal-endothelial-disease

Related to this article